Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Brief Report: Leucine-Rich α2 -Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis.

Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T.

Arthritis Rheumatol. 2015 May;67(8):2056-60. doi: 10.1002/art.39164.

PMID:
25917892
2.

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.

Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group.

Arthritis Res Ther. 2015 Mar 23;17:74. doi: 10.1186/s13075-015-0583-8.

3.

Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study.

Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiyama H, Kohsaka H, Miyasaka N, Harigai M; PREVENT Study Group.

J Rheumatol. 2015 Apr;42(4):614-22. doi: 10.3899/jrheum.140778. Epub 2015 Feb 1.

PMID:
25641893
4.

Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia.

Tanaka M, Koike R, Sakai R, Saito K, Hirata S, Nagasawa H, Kameda H, Hara M, Kawaguchi Y, Tohma S, Takasaki Y, Dohi M, Nishioka Y, Yasuda S, Miyazaki Y, Kaneko Y, Nanki T, Watanabe K, Yamazaki H, Miyasaka N, Harigai M.

Mod Rheumatol. 2015 Jul;25(4):609-14. doi: 10.3109/14397595.2014.980384. Epub 2014 Dec 15.

PMID:
25496409
5.

Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.

Miyabe Y, Miyabe C, Iwai Y, Yokoyama W, Sekine C, Sugimoto K, Harigai M, Miyasaka M, Miyasaka N, Nanki T.

Arthritis Res Ther. 2014 Oct 2;16(5):461. doi: 10.1186/s13075-014-0461-9.

6.

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice.

Yokoyama W, Kohsaka H, Kaneko K, Walters M, Takayasu A, Fukuda S, Miyabe C, Miyabe Y, Love PE, Nakamoto N, Kanai T, Watanabe-Imai K, Charvat TT, Penfold ME, Jaen J, Schall TJ, Harigai M, Miyasaka N, Nanki T.

Arthritis Res Ther. 2014 Sep 24;16(5):445. doi: 10.1186/s13075-014-0445-9.

7.

Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis.

Fukuda S, Kohsaka H, Takayasu A, Yokoyama W, Miyabe C, Miyabe Y, Harigai M, Miyasaka N, Nanki T.

BMC Musculoskelet Disord. 2014 Aug 12;15:275. doi: 10.1186/1471-2474-15-275.

8.
9.

Could retinoids be a potential treatment for rheumatic diseases?

Miyabe Y, Miyabe C, Nanki T.

Rheumatol Int. 2015 Jan;35(1):35-41. doi: 10.1007/s00296-014-3067-2. Epub 2014 Jun 18.

PMID:
24939557
10.

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.

Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group.

Rheumatol Int. 2014 Dec;34(12):1729-36. doi: 10.1007/s00296-014-3045-8. Epub 2014 May 23.

PMID:
24852650
11.

Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG.

Umezawa N, Kohsaka H, Nanki T, Watanabe K, Tanaka M, Shane PY, Miyasaka N.

Mod Rheumatol. 2014 Jul;24(4):685-7. doi: 10.3109/14397595.2013.874734. Epub 2014 Feb 11.

PMID:
24517553
12.

Recurrent mitral valve regurgitation with neutrophil infiltration in a patient with multiple aseptic abscesses.

Fukuda S, Nanki T, Morio T, Hasegawa H, Koike R, Miyasaka N.

Mod Rheumatol. 2014 May;24(3):537-9. doi: 10.3109/14397595.2013.852853. Epub 2014 Feb 7.

PMID:
24506570
13.

Serodiagnosis of Mycobacterium avium complex pulmonary disease in rheumatoid arthritis.

Komazaki Y, Miyazaki Y, Fujie T, Sakashita H, Tsuchiya K, Tamaoka M, Sumi Y, Maruyama Y, Nanki T, Inase N.

Respiration. 2014;87(2):129-35. doi: 10.1159/000354791. Epub 2013 Dec 4.

PMID:
24335035
14.

A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.

Cho SK, Sakai R, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Tanaka Y, Nakajima A, Yasuda S, Ihata A, Ezawa K, Won S, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Miyasaka N, Bae SC, Harigai M; RESEARCH investigators; REAL Study Group.

Mod Rheumatol. 2014 Jul;24(4):572-9. doi: 10.3109/14397595.2013.860695. Epub 2013 Dec 9.

PMID:
24320747
15.

CCL18 activates fibroblast-like synoviocytes in patients with rheumatoid arthritis.

Takayasu A, Miyabe Y, Yokoyama W, Kaneko K, Fukuda S, Miyasaka N, Miyabe C, Kubota T, Nanki T.

J Rheumatol. 2013 Jun;40(6):1026-8. doi: 10.3899/jrheum.121412. No abstract available.

PMID:
23728190
16.

Necessity of lysophosphatidic acid receptor 1 for development of arthritis.

Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, Yokoyama W, Nagai J, Jona M, Tokuhara Y, Ohkawa R, Albers HM, Ovaa H, Aoki J, Chun J, Yatomi Y, Ueda H, Miyasaka M, Miyasaka N, Nanki T.

Arthritis Rheum. 2013 Aug;65(8):2037-47. doi: 10.1002/art.37991.

PMID:
23666827
17.

Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections.

Nanki T, Onoue I, Nagasaka K, Takayasu A, Ebisawa M, Hosoya T, Shirai T, Sugihara T, Hirata S, Kubota T, Harigai M, Miyasaka N.

Ann Rheum Dis. 2013 Jun;72(6):1100-2. doi: 10.1136/annrheumdis-2012-202768. Epub 2013 Jan 24. No abstract available.

PMID:
23349134
18.

CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4.

Uto-Konomi A, McKibben B, Wirtz J, Sato Y, Takano A, Nanki T, Suzuki S.

Biochem Biophys Res Commun. 2013 Feb 22;431(4):772-6. doi: 10.1016/j.bbrc.2013.01.032. Epub 2013 Jan 16.

PMID:
23333329
19.
20.

Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.

Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, Komano Y, Akiyama Y, Mimura T, Kaneko M, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Mukai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M.

Mod Rheumatol. 2013 Nov;23(6):1085-93. doi: 10.1007/s10165-012-0796-5. Epub 2012 Dec 5.

PMID:
23212592
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk